Event-Driven Stocks

Vir Biotechnology, Inc.

VIRNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 4 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$68.6M$74.2M$86.2M$1.62B$1.10B$5.7M
Operating income−$479.3M−$587.2M−$684.3M$833.1M$420.8M−$297.0M
Net income−$438.0M−$522.0M−$615.1M$515.8M$528.6M−$77.2M
Total assets$1.00B$1.40B$1.92B$2.80B$1.95B$918.8M
Total liabilities$237.5M$248.4M$328.8M$724.1M$522.4M$201.9M
Equity$765.3M$1.15B$1.59B$2.08B$1.43B$716.9M
EPS (diluted)$-3.16$-3.83$-4.59$3.83$3.96$-0.71
Shares out.137.1M135.0M133.5M132.3M127.8M109.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−699.2%
Net margin
−638.9%
Return on equity
−57.2%
Return on assets
−43.7%
Return on capital (ROCE)
−52.7%
Liabilities / assets
23.7%
Debt / equity
0.31×
Book value / share
$5.58
Revenue growth (YoY)
−7.6%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-0.97distress
Accruals / assets
−4.6%clean
Piotroski F-Score
3/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
42
/ 100
Profitability 0Growth 0Catalyst 67Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 4 warning● 2 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202616.8M10.9+4.4%
Apr 30, 202616.1M9.7-4.1%
Apr 15, 202616.8M8.8-0.2%
Mar 31, 202616.8M7.7+9.1%
Mar 13, 202615.4M3.7+12.9%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.